Request Demo
Last update 02 May 2026
Fianlimab/Cemiplimab
Last update 02 May 2026
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms- |
Target |
Action inhibitors, modulators |
Mechanism LAG3 inhibitors(Lymphocyte activation gene 3 protein inhibitors), PD-1 inhibitors(Programmed cell death protein 1 inhibitors), Cells modulators |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 13378488H
The sequence is quoted from: *****
Sequence Code 13378495L
The sequence is quoted from: *****
Sequence Code 13451140H
The sequence is quoted from: *****
Sequence Code 13451157L
The sequence is quoted from: *****
Related
8
Clinical Trials associated with Fianlimab/CemiplimabNCT07365839
CLeAR: Pilot Study to Evaluate the Efficacy of Cemiplimab (PD-1 Inhibition) With or Without Fianlimab (LAG-3 Inhibition) After Y90 Radioembolization in Patients With Hepatocellular Carcinoma
NCT07414992
Neoadjuvant STereotActic Body Radiotherapy and Cemiplimab With or Without Fianlimab for Cisplatin-Ineligible or Cisplatin-Declining Patients With Muscle-Invasive Bladder Cancer (NeoSTAR Bladder)
NCT07527325
Fianlimab and Cemiplimab as Total Neoadjuvant Therapy (TNT) For Melanoma
100 Clinical Results associated with Fianlimab/Cemiplimab
Login to view more data
100 Translational Medicine associated with Fianlimab/Cemiplimab
Login to view more data
100 Patents (Medical) associated with Fianlimab/Cemiplimab
Login to view more data
100 Deals associated with Fianlimab/Cemiplimab
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Unresectable Melanoma | Phase 3 | United States | 09 Sep 2024 | |
| Unresectable Melanoma | Phase 3 | Canada | 09 Sep 2024 | |
| Muscle Invasive Bladder Carcinoma | Phase 2 | United States | 01 May 2026 | |
| Urothelial Carcinoma of the Urinary Bladder | Phase 2 | United States | 01 May 2026 | |
| Advanced Renal Cell Carcinoma | Phase 2 | United States | 29 Apr 2026 | |
| Metastatic Renal Cell Carcinoma | Phase 2 | United States | 29 Apr 2026 | |
| Squamous Cell Carcinoma of Head and Neck | Phase 2 | United States | 31 Mar 2026 | |
| Stage III Colon Cancer | Phase 2 | - | 01 Feb 2026 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free